Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
The AAPS Journal|December 6, 2013
Plant phytochemicals as epigenetic modulators: role in cancer chemopreventionVijay S Thakur, Gauri Deb, Melissa A Babcook, et al.
Genomics Data|October 21, 2015
Expression profiling of genes modulated by estrogen, EGCG or both in MCF-7 breast cancer cellsMohan C Manjegowda, Gauri Deb, Neeraj Kumar, et al.
Leukemia & Lymphoma|October 11, 2022
Perturbation of the gut microbiome and association with outcomes following autologous stem cell transplantation in patients with multiple myelomaChristopher D'Angelo, Sailendharan Sudakaran, Fotis Asimakopoulos, et al.
Trends in Immunology|June 9, 2026
A pancreatic intraepithelial neoplasia-Oramic view of early pancreatic cancer in 3DAlexander Cicala, Sebastian A Dziadowicz, Peter M K Westcott
The Journal of Biological Chemistry|December 4, 2015
Loss of SIRT3 Provides Growth Advantage for B Cell MalignanciesWei Yu, Ryan A Denu, Kimberly A Krautkramer, et al.
British Journal of Haematology|May 16, 2012
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cellsJaehyup Kim, Ryan A Denu, Bridget A Dollar, et al.
Molecular Carcinogenesis|March 12, 2019
Green tea-induced epigenetic reactivation of tissue inhibitor of matrix metalloproteinase-3 suppresses prostate cancer progression through histone-modifying enzymesGauri Deb, Eswar Shankar, Vijay S Thakur, et al.
Journal of Translational Medicine|November 12, 2022
Differential regulation of TNFα and IL-6 expression contributes to immune evasion in prostate cancerIda Deichaite, Timothy J Sears, Leisa Sutton, et al.
Leukemia & Lymphoma|February 26, 2013
Macrophages in multiple myeloma: emerging concepts and therapeutic implicationsFotis Asimakopoulos, Jaehyup Kim, Ryan A Denu, et al.
Cancer Chemotherapy and Pharmacology|August 30, 2014
Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology NetworkNatalie Callander, Stephanie Markovina, Jens Eickhoff, et al.
Pageof 6